Scarica l'app Stockscreener
5.49
3.68%
-0.21
Dopo l'orario di chiusura:
5.49
Precedente Chiudi:
$5.70
Aprire:
$5.74
Volume 24 ore:
6,799
Relative Volume:
0.25
Capitalizzazione di mercato:
$43.28M
Reddito:
$1.11M
Utile/perdita netta:
$-28.25M
Rapporto P/E:
-0.4467
EPS:
-12.2899
Flusso di cassa netto:
$-22.13M
1 W Prestazione:
-3.17%
1M Prestazione:
+14.16%
6M Prestazione:
+7.44%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$5.49
$5.74
Intervallo di 1 settimana:
$5.21
$5.92
Portata 52W:
$3.4962
$50.82
Radiopharm Theranostics Ltd Adr Stock (RADX) Company Profile
Nome
Radiopharm Theranostics Ltd Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta RADX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RADX
Radiopharm Theranostics Ltd Adr
|
5.49 | 44.35M | 1.11M | -28.25M | -22.13M | -12.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Radiopharm Theranostics Ltd Adr Stock (RADX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-12 | Iniziato | B. Riley Securities | Buy |
Radiopharm Theranostics Ltd Adr Borsa (RADX) Ultime notizie
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Jazz Pharmaceuticals (JAZZ) - The Globe and Mail
Radiopharm Theranostics Hosts Webinar Series on Radiopharmaceutical Therapies - MSN
Radiopharm Theranostics: Promising Pipeline and Strategic Advancements Drive Buy Rating - TipRanks
Radiopharm Theranostics Limited: Promising Clinical Developments and Strategic Growth Potential Drive Buy Rating - TipRanks
FDA clears Radiopharm’s IND application for Lu177-B7H3 antibody By Investing.com - Investing.com India
FDA clears Radiopharm’s IND application for Lu177-B7H3 antibody - Investing.com
Radiopharm Theranostics receives FDA IND approval for Betabart (RV-01) By Investing.com - Investing.com India
Radiopharm Theranostics receives FDA IND approval for Betabart (RV-01) - Investing.com
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board - GlobeNewswire Inc.
Radiopharm Theranostics adds Dr Oliver Sartor to scientific advisory board By Investing.com - Investing.com India
Radiopharm Theranostics adds Dr Oliver Sartor to scientific advisory board - Investing.com
Radiopharm Theranostics (NASDAQ:RADX) Now Covered by Brookline Capital Management - Defense World
Radiopharm Theranostics stock initiated with Buy rating at Brookline Capital - Investing.com
Radiopharm Theranostics stock initiated with Buy rating at Brookline Capital By Investing.com - Investing.com India
Radiopharm Theranostics receives $4.5 million R&D tax incentive - Investing.com India
Radiopharm Theranostics receives $4.5 million R&D tax incentive By Investing.com - Investing.com South Africa
OKYO Pharma (NASDAQ:OKYO) Trading Up 1% – Here’s Why - Defense World
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and COMPASS Pathways (CMPS) - The Globe and Mail
Radiopharm signs supply agreement with Cyclotek for prostate cancer drug - Investing.com
Radiopharm wins FDA fast track for cancer imaging agent By Investing.com - Investing.com South Africa
Radiopharm wins FDA fast track for cancer imaging agent - Investing.com
Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
radiopharm theranostics begins patient dosing in new trial - Investing.com
radiopharm theranostics begins patient dosing in new trial By Investing.com - Investing.com India
radiopharm theranostics shares preclinical data on new cancer therapy By Investing.com - Investing.com South Africa
radiopharm theranostics shares preclinical data on new cancer therapy - Investing.com
Radiopharm secures lutetium-177 supply agreement By Investing.com - Investing.com South Africa
Radiopharm Theranostics Secures Lutetium-177 Supply Agreement with ITM - TipRanks
Radiopharm secures lutetium-177 supply agreement - Investing.com
Radiopharm advances RAD204 trial with expedited phase By Investing.com - Investing.com India
Radiopharm advances RAD204 trial with expedited phase - Investing.com
RADX: Initiating Coverage – Adding a Radioisotope to Precision Oncology - Zacks Small Cap Research
ThinkEquity initiates Radiopharm stock with Buy, $15 target By Investing.com - Investing.com India
ThinkEquity initiates Radiopharm stock with Buy, $15 target - Investing.com
Radiopharm advances brain cancer diagnosis with new trial By Investing.com - Investing.com South Africa
Radiopharm advances brain cancer diagnosis with new trial - Investing.com
Radiopharm Theranostics says new data confirms positive tumour uptake - Biotech Dispatch
Radiopharm Theranostics Engages in Key Healthcare Conferences - TipRanks
B.Riley sets $15 target on Radiopharm Theranostics stock - Investing.com India
Radiopharm Theranostics Announces Director’s Interest Change and Securities Cessation - TipRanks
Radiopharm joins B Riley Radiopharma Conference - Investing.com
Radiopharm reveals positive brain metastases trial data - Investing.com
Top 3 Health Care Stocks You'll Regret Missing This Month - Benzinga
Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday - Benzinga
Radiopharm Theranostics Ltd Adr Azioni (RADX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.96%
1.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):